Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors

Cytotherapy

Volumn 16, Issue 10, 2014, Pages 1390-1408

  Beloki, Lorea ^a   Ramírez, Natalia ^a   Olavarría, Eduardo ^a,b   Samuel, Edward R ^c   Lowdell, Mark W ^c  

^a Atención Primaria Y Promoción de La Salud   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic hematopoietic stem cell transplantation; CD137; Cytomegalovirus specific T cells; Granulocyte colony stimulating factor; Immunotherapy

Indexed keywords

CD137 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANZYME B; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DONOR; ENZYME RELEASE; FEASIBILITY STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; STEM CELL MOBILIZATION; T LYMPHOCYTE; VIRUS REACTIVATION; ADULT; ADVERSE EFFECTS; CELL CULTURE; CELL SEPARATION; CYTOLOGY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LEUKAPHERESIS; MALE; MIDDLE AGED; MONONUCLEAR CELL; PHYSIOLOGY; PROCEDURES; VIRUS ACTIVATION;

CYTOMEGALOVIRUS;

ADULT; CELL SEPARATION; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKAPHERESIS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TISSUE DONORS; VIRUS ACTIVATION;

EID: 84908498511     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.05.009     Document Type: Article

References (53)

1. Sellar R.S., Peggs K.S. Therapeutic strategies for the prevention and treatment of cytomegalovirus infection. Expert Opin Biol Ther 2012, 12:1161-1172.
2. Ljungman P., de la Camara R., Cordonnier C., Einsele H., Engelhard D., Reusser P., et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008, 42:227-240.
3. Busca A. Cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation: significant progress, but many unresolved problems. Expert Opin Biol Ther 2009, 9:383-385.
4. Boeckh M., Leisenring W., Riddell S.R., Bowden R.A., Huang M.L., Myerson D., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
5. Meijer E., Boland G.J., Verdonck L.F. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev 2003, 16:647-657.
6. Li C.R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
7. Battiwalla M., Wu Y., Bajwa R.P., Radovic M., Almyroudis N.G., Segal B.H., et al. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 2007, 13:765-770.
8. Tormo N., Solano C., Benet I., Nieto J., de la Camara R., Lopez J., et al. Reconstitution of CMV pp65 and IE-1-specific IFN-gamma CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant 2011, 46:1437-1443.
9. Hakki M., Riddell S.R., Storek J., Carter R.A., Stevens-Ayers T., Sudour P., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003, 102:3060-3067.
10. Ramirez N., Beloki L., Ciaurriz M., Rodriguez-Calvillo M., Escors D., Mansilla C., et al. Impact of T cell selection methods in the success of clinical adoptive immunotherapy. Cell Mol Life Sci 2014, 71:1211-1224.
11. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
12. Peggs K.S., Verfuerth S., Pizzey A., Chow S.L., Thomson K., Mackinnon S. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009, 49:1851-1860.
13. Sun Q., Pollok K.E., Burton R.L., Dai L.J., Britt W., Emanuel D.J., et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood 1999, 94:3242-3250.
14. Kessels H.W., Wolkers M.C., van den Boom M.D., van der Valk M.A., Schumacher T.N. Immunotherapy through TCR gene transfer. Nat Immunol 2001, 2:957-961.
15. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
16. Micklethwaite K.P., Savoldo B., Hanley P.J., Leen A.M., Demmler-Harrison G.J., Cooper L.J., et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010, 115:2695-2703.
17. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
18. Ramirez N., Olavarria E. Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies. Bone Marrow Transplant 2013, 48:1265-1270.
19. Peggs K.S., Thomson K., Samuel E., Dyer G., Armoogum J., Chakraverty R., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52:49-57.
20. Feuchtinger T., Opherk K., Bethge W.A., Topp M.S., Schuster F.R., Weissinger E.M., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
21. Frentsch M., Arbach O., Kirchhoff D., Moewes B., Worm M., Rothe M., et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 2005, 11:1118-1124.
22. Gallot G., Vivien R., Ibisch C., Lule J., Davrinche C., Gaschet J., et al. Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection, I: application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination. JImmunol 2001, 167:4196-4206.
23. Wolfl M., Kuball J., Ho W.Y., Nguyen H., Manley T.J., Bleakley M., et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110:201-210.
24. Han S., Huang Y., Liang Y., Ho Y., Wang Y., Chang L.J. Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. JHematol Oncol 2009, 2:34.
25. Samuel E.R., Newton K., Mackinnon S., Lowdell M.W. Successful isolation and expansion of CMV-reactive T cells from G-CSF mobilized donors that retain a strong cytotoxic effector function. Br J Haematol 2013, 160:87-100.
26. Clancy L.E., Blyth E., Simms R., Micklethwaite K.P., Kris Ma C.K., Burgess J., et al. CMV-specific cytotoxic T lymphocytes can be efficiently expanded from G-CSF mobilised haemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplant recipients to facilitate immune reconstitution. Biol Blood Marrow Transplant 2013, 19:725-734.
27. Rutella S., Zavala F., Danese S., Kared H., Leone G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. JImmunol 2005, 175:7085-7091.
28. Rossetti M., Gregori S., Roncarolo M.G. Granulocyte-colony stimulating factor drives the in vitro differentiation of human dendritic cells that induce anergy in naive T cells. Eur J Immunol 2010, 40:3097-3106.
29. Toh H.C., Sun L., Soe Y., Wu Y., Phoon Y.P., Chia W.K., et al. G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo. Clin Immunol 2009, 132:83-92.
30. Bunse C.E., Borchers S., Varanasi P.R., Tischer S., Figueiredo C., Immenschuh S., et al. Impaired functionality of antiviral T cells in G-CSF mobilized stem cell donors: implications for the selection of CTL donor. PLoS One 2013, 8:e77925.
31. Otto M., Barfield R.C., Iyengar R., Gatewood J., Muller I., Holladay M.S., et al. Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. JImmunother 2005, 28:73-78.
32. Samuel E.R., Beloki L., Newton K., Mackinnon S., Lowdell M.W. Isolation of highly suppressive CD25+FoxP3+ T regulatory cells from G-CSF-mobilized donors with retention of cytotoxic anti-viral CTLs: application for multi-functional immunotherapy post stem cell transplantation. PLoS One 2014, 9:e85911.
33. Ukena S.N., Velaga S., Goudeva L., Ivanyi P., Olek S., Falk C.S., et al. Human regulatory T cells of G-CSF mobilized allogeneic stem cell donors qualify for clinical application. PLoS One 2012, 7:e51644.
34. Lugthart G., Albon S.J., Ricciardelli I., Kester M.G., Meij P., Lankester A.C., et al. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. JImmunother 2012, 35:42-53.
35. Leibold J., Feucht J., Halder A., Stevanovic S., Kayser S., Handgretinger R., et al. Induction of Thelper1-driven antiviral T-cell lines for adoptive immunotherapy is determined by differential expression of IFN-gamma and T-cell activation markers. JImmunother 2012, 35:661-669.
36. Zhang X., Voskens C.J., Sallin M., Maniar A., Montes C.L., Zhang Y., et al. CD137 promotes proliferation and survival of human B cells. JImmunol 2010, 184:787-795.
37. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
38. Wehler T.C., Karg M., Distler E., Konur A., Nonn M., Meyer R.G., et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. JImmunol Methods 2008, 339:23-37.
39. Surh C.D., Boyman O., Purton J.F., Sprent J. Homeostasis of memory T cells. Immunol Rev 2006, 211:154-163.
40. Cwynarski K., Ainsworth J., Cobbold M., Wagner S., Mahendra P., Apperley J., et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001, 97:1232-1240.
41. Pourgheysari B., Piper K.P., McLarnon A., Arrazi J., Bruton R., Clark F., et al. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 2009, 43:853-861.
42. Moss P., Khan N. CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 2004, 65:456-464.
43. Crough T., Fazou C., Weiss J., Campbell S., Davenport M.P., Bell S.C., et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response. JVirol 2007, 81:11538-11542.
44. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. JClin Invest 2005, 115:1616-1626.
45. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006, 6:383-393.
46. Focosi D., Bestagno M., Burrone O., Petrini M. CD57+ T lymphocytes and functional immune deficiency. JLeukoc Biol 2010, 87:107-116.
47. Brenchley J.M., Karandikar N.J., Betts M.R., Ambrozak D.R., Hill B.J., Crotty L.E., et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003, 101:2711-2720.
48. Ewen C.L., Kane K.P., Bleackley R.C. Aquarter century of granzymes. Cell Death Differ 2012, 19:28-35.
49. Harty J.T., Badovinac V.P. Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 2008, 8:107-119.
50. Appay V., Zaunders J.J., Papagno L., Sutton J., Jaramillo A., Waters A., et al. Characterization of CD4(+) CTLs ex vivo. JImmunol 2002, 168:5954-5958.
51. Luckheeram R.V., Zhou R., Verma A.D., Xia B. CD4(+)T cells: differentiation and functions. Clin Dev Immunol 2012, 2012:925135.
52. Slezak S.L., Bettinotti M., Selleri S., Adams S., Marincola F.M., Stroncek D.F. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. JTransl Med 2007, 5:17.
53. Morita Y., Hosokawa M., Ebisawa M., Sugita T., Miura O., Takaue Y., et al. Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 orHLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:803-811.